Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61-3-8532-2700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.79 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
STARPHARMA HOLD/S (OTCMKTS:SPHRY) Frequently Asked Questions
What is STARPHARMA HOLD/S's stock symbol?
STARPHARMA HOLD/S trades on the OTCMKTS under the ticker symbol "SPHRY."
Has STARPHARMA HOLD/S been receiving favorable news coverage?
News articles about SPHRY stock have trended somewhat positive on Friday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. STARPHARMA HOLD/S earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for STARPHARMA HOLD/S.
Who are some of STARPHARMA HOLD/S's key competitors?
Some companies that are related to STARPHARMA HOLD/S include Intrexon (XON), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Geovax Labs (GOVX), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), US Stem Cell (USRM) and Vitality Biopharma (VBIO).
What other stocks do shareholders of STARPHARMA HOLD/S own?
Who are STARPHARMA HOLD/S's key executives?
STARPHARMA HOLD/S's management team includes the folowing people:
- Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 56)
- Mr. Nigel J. Baade, CFO & Company Sec.
- Dr. A. Eglezos BSc(Hons), Ph.D., MBA, VP of Bus. Devel.
- Dr. Jeremy R. Paull BSc (Hons), Ph.D., VP of Devel. & Regulatory Affairs
- Dr. David J. Owen BSc(Hons) Ph.D., VP of Research
How do I buy shares of STARPHARMA HOLD/S?
Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is STARPHARMA HOLD/S's stock price today?
One share of SPHRY stock can currently be purchased for approximately $8.13.
How big of a company is STARPHARMA HOLD/S?
What is STARPHARMA HOLD/S's official website?
How can I contact STARPHARMA HOLD/S?
STARPHARMA HOLD/S's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at 61-3-8532-2700 or via email at [email protected]
MarketBeat Community Rating for STARPHARMA HOLD/S (OTCMKTS SPHRY)
MarketBeat's community ratings are surveys of what our community members think about STARPHARMA HOLD/S and other stocks. Vote "Outperform" if you believe SPHRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
